[e-drug] Medicine Pricing Matters, Issue 6

E-DRUG: Medicine Pricing Matters, Issue 6
----------------------------------

The 6th issue of Medicine Pricing Matters, the bulletin of the WHO/HAI Project on Medicine Prices and Availability, is now available on HAI's website: http://www.haiweb.org/medicineprices.

Taxes on essential medicines target the sick, who are least able to pay - this regressive policy, which has coincidentally been discussed on e-drug over the last few days, is the subject of one of the articles in the latest issue of Medicine Pricing Matters.

The bulletin also features a two page spread on medicine price, availability and affordability issues in four Latin American countries; Bolivia, Colombia, Ecuador and Nicaragua. In addition to outlining key findings from recent price and availability surveys, the HAI groups who undertook this work briefly comment on the reality of ineffective national price policies and propose strategies to improve the situation.

Two other articles feature in the bulletin; the results of a price survey in São Tomé and Príncipe, and a study on access to diabetes care in the Philippines. A diabetic interviewed in the Philippines study said it all ' I cannot accept that I have diabetes. ...I am scared of losing all properties just because of diabetes. I know that it is expensive to have a disease like this.'

Go to http://www.haiweb.org/medicineprices to access the bulletin, survey reports and data, and other work of the WHO/HAI Project on Medicine Prices and Availability.

Regards,

Martin Auton, Global Projects Officer (Pricing)
HAI Global
Overtoom 60/III
1054 HK Amsterdam
The Netherlands
Tel: +31 20 683 3684
Fax: +31 20 685 5002
Email: martin@haiweb.org
Web site: http://www.haiweb.org

E-DRUG: Medicine Pricing Matters (2)
------------------------------

Dear All,

Please see the following news published in Pharmatimes today.
http://www.pharmatimes.com/WorldNews/article.aspx?id=17311&src=EWorldNews
[Copied as fair use]

300 branded drug prices slashed in Ireland
02 February 2010
By Lynne Taylor

Research-based drugmakers in Ireland cut the prices of almost 300 of their most widely-prescribed medicines by 40% yesterday, in a move aimed at saving the state 94 million euros over the next full year.

The Irish Pharmaceutical Healthcare Association (IPHA) said it had agreed the price cuts after being approached by Mary Harney, the Minister for Health and Children, with a request to create immediate savings on the state bill for medicines. As a result of the 40% reductions, the patented drugs on the list are now cheaper than their generic versions, and customers should save 3-4 euros each time their prescription is dispensed - potentially as much as 500 euros a year, said the Association, which has set up a website, www.checkthelist.ie, for consumers to check which products are now cheaper. They can also call 1890 876 700 for this information.

IPHA members have also agreed to pay an increased rebate to Ireland’s Health Service Executive (HSE) in respect of the manufacturer price of all other medicines dispensed under the nation’s Community Drug Schemes, the Association added.

However, pharmacists are under no obligation to pass on the new lower prices to consumers, and the Irish Pharmacy Union (IPU), which represents community pharmacists, has pointed out that pharmacists had not been permitted to start purchasing medicines at the new lower prices in advance of the reductions.

“This means that the medicines, which pharmacists stock on their shelves for patients on behalf of the HSE, will now be paid for by the HSE at the new lower rates, despite having been purchased by pharmacists at the high prices which were previously agreed between the HSE and the drug companies,” said IPU president Liz Hoctor, who described this “discrepancy” as “yet another severe financial blow for pharmacists.”

The price cuts may also hit the thriving border trade built up by pharmacists in Northern Ireland, who have been permitted to fill prescriptions for residents of the Republic who pay for their prescriptions since changes in European Union (EU) regulations took effect in November 2008.

Ms Harney has yet to secure a similar price-cutting undertaking from generics makers, which are represented by the Association of Pharmaceutical Manufacturers in Ireland (APMI). The Minister said she was disappointed that APMI members have “declined to offer any reductions,” but warned them that it is her “firm intention to obtain savings from APMI of at least an equivalent level to those secured from IPHA,” totaling a further 27 million euros in a full year.

The Irish government’s current pricing agreement with the APMI runs out on September 1, while a new deal with makers of branded medicines is due to take effect in March 2012.

- Ms Harney has also confirmed that Ireland’s controversial new 50-cent prescription charge, to be imposed on each prescription item dispensed to the Republic’s 1.4 million medical card-holders under the Community Drugs Schemes, is expected to be introduced on April 1. Taoiseach (Prime Minister) Brian Cowen has defended the new charge, saying it will generate savings of some 30 million euros a year. Ireland’s drugs bill is forecast to reach 3 billion euros for 2010.

E-DRUG: Medicine prices and government taxes
--------------------------------------

Dear All,

Apropos of Dr Chandra Gulhati's message reference import tariffs on medicines, I would like to reiterate that the idea of campaigning against government levies and taxes (on API and finished products, locally manufactured and imported) as the main strategy for reduction in prices may not be such a good idea after all. Here below are just a few reasons:

1. Government taxes and duties are levied as a percentage of the importer and/or manufacturer base price and as such they are directly proportionate - the higher the base prices the higher the amount of taxes and duties. If the base prices are low government taxes and duties in real terms would automatically come down.

2. Levying taxes and duties is a sovereign prerogative of national governments taken in context of fiscal policy and economic fundamentals. Besides, such levies add to the public revenue for welfare of the people of the country. Therefore taxes and duties components of the medicine prices are not fundamentally wrong and should not to be prime targets for price reductions. However, concerned citizen must focus on 'excessive' and 'abusive' taxation and advocate for making the same more rational and conducive to ensure access to medicines.

3. There is tremendous amount of information available to show that the base prices are fantastically exaggerated. In Pakistan we have hundreds of medicines in which base prices of medicines are set at thousands of times higher than their actual cost at the factory/warehouse gate.

In view of these submissions I would like to urge HAI/WHO Project on Medicine Prices and Availability that the campaign on reduction in medicine prices should be reviewed to bring the focus on industry prices rather than government taxes.

With kind regards,

Ayyaz

E-DRUG: Medicine prices and government taxes (2)
----------------------------------------

Those interested in this topic may find the policy paper prepared by
the Global Health Council useful. It can be accessed at
http://www.globalhealth.org/images/pdf/publications/tarrifs_09_2007.pdf .

Government tariffs on medicines do no more than to raise the cost
of medicines. The total revenue raised is simply too small that its
absence could not be replaced with other mechanisms not the least of
which is the savings to patients that ultimately benefit health
budgets.

Michele Forzley, JD, MPH
301-565-0680
michele@micheleforzley.com